Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
A new HANDling of progressive MS and progressive MS trials.
[Not Available].
Differences in Physical and Cognitive Function among Caucasian and African American Adults with Multiple Sclerosis.
Reactive species as regulators of immune cell metabolism, tolerance, and autoimmunity.
Targeting IL-33 in Precision Neuroimmunology: Cellular Mechanisms and Therapeutic Strategies for CNS Disorders.
Neuromyelitis optica presenting with mammillary body and cervicomedullary lesions after severe hyponatremia mimicking osmotic demyelination syndrome.
FDA's Approval Summary of the First Biosimilar to Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease.
Dynamics of Myelin-Specific T-Cell Repertoires Mirror Disease Activity and Central Nervous System Trafficking in Multiple Sclerosis.
The effect of progressive muscle relaxation on intimacy and sexuality in women with multiple sclerosis: A single-blinded randomized controlled trial.
A novel anti-CD20, concabody, enhances immunotherapy efficacy by targeting MPZL1 and augmenting antibody-induced cell death.
Association of elevated asymmetric dimethylarginine (ADMA) with subclinical carotid atherosclerosis in multiple sclerosis: A cross-sectional biomarker study.
Assessment of serum FAM19A5 level in patients with Neuromyelitis Optica spectrum disorder.
Biomaterials and Nanoparticle-Based Therapeutics in Neurodegenerative Diseases: Bridging the Gap Between Innovation and Translation.
Neurodegenerative Diseases in Children: A Comprehensive Review.
Is supplemental vitamin D useful in the clinically isolated syndrome (CIS) typical of multiple sclerosis?
Interleukin-40 and Soluble CD40 Ligand in Multiple Sclerosis: Inflammatory Signals or Clinically Applicable Biomarkers?
Socioeconomic impact of depression and pain in patients with neuromyelitis optica spectrum disorders.
Neurophysiological, imaging and neurobiological markers of central fatigue in multiple sclerosis.
Study on chimeric recombinant spider silk protein-P(LLA-CL) material for facial nerve repair in sd rats.
Recalibration and external validation of vascular risk calculators for multiple sclerosis: A population-based study using CPRD data in England, 1987-2023.
A novel limited-dose C5 inhibitor add-on as rescue therapy for refractory NMOSD attacks: a practical alternative to conventional multi-dose regimens.
Disentangling verbal learning performance in multiple sclerosis: Dissociating strategy initiation and maintenance.
Case 346: γ-Aminobutyric Acid A Receptor Encephalitis.
Srrm2 haploinsufficiency drives SynGAP-γ reduction, Agap3 mis-splicing, and oligodendrocyte deficits in a genetic mouse model of schizophrenia.
Maintenance intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: trends from an Australian tertiary centre.
Pages
« first
‹ previous
…
856
857
858
859
860
861
862
863
864
…
next ›
last »